1. Mouse resident peritoneal macrophages in culture modified human 125I-labelled low-density lipoprotein (LDL) to a form that other macrophages took up about 10 times as fast as unmodified LDL. The modified LDL was toxic to macrophages in the absence of serum. 2. There was a lag phase of about 4-6 h before the LDL was modified so that macrophages took it up faster. A similar time lag was observed when LDL was oxidized by 5,M-CuSO4 in the absence of cells. 3. LDL modification was maximal when about 1.5 x 106 peritoneal cells were plated per 22.6 mm-diam. well. 4. Re-isolated macrophage-modified LDL was also taken up much faster by macrophages, indicating that the increased uptake was due to a change in the LDL particle itself. 5. Micromolar concentrations of iron were required for the modification of LDL by macrophages to take place. The nature of the other components in the culture medium was also important. Macrophages would modify LDL in Ham's F-1O medium but not in Dulbecco's modified Eagle's medium, even when iron was added to it. 6. The macrophage-modified LDL appeared to be taken up almost entirely via the acetyl-LDL receptor. 7. LDL modification by macrophages was inhibited partially by EDTA and desferrioxamine and completely by the general free radical scavengers butylated hydroxytoluene, vitamin E and nordihydroguaiaretic acid. It was also inhibited completely by low concentrations of foetal calf serum and by the anti-atherosclerotic drug probucol. It was not inhibited by the cyclo-oxygenase inhibitors acetylsalicylic acid and indomethacin. 8. Macrophages are a major cellular component of atherosclerotic lesions and the local oxidation of LDL by these cells may contribute to their conversion into cholesterolladen foam cells in the arterial wall.
INTRODUCTION
Low-density lipoprotein (LDL) has been heavily implicated in the pathogenesis of atherosclerosis, the underlying cause of heart attacks and strokes. It was shown by Henriksen et al. (1981) that LDL could be modified by arterial endothelial cells in culture so that it was taken up faster by macrophages. As macrophages accumulate much of the cholesterol and cholesteryl esters that are deposited in atherosclerotic lesions (Leary, 1941; Poole & Florey, 1958; Fowler et al., 1979) , this observation may help to explain why these cells are converted into lipid-laden foam cells in this disease. Endothelial-cell-modified LDL is taken up rapidly by receptors on macrophages which are known as scavenger receptors or acetyl-LDL receptors. Scavenger receptors have recently been cloned and sequenced Rohrer et al., 1990) , but the exact number and nature of distinct receptors that mediate the uptake of cell-modified LDL is still unclear (Sparrow et al., 1989; Arai et al., 1989) . Native (i.e. unmodified) LDL is not recognized by these receptors and is taken up only slowly by a limited number of LDL receptors on macrophages. Modified LDL, but not native LDL, therefore induces large-scale cholesteryl ester accumulation in macrophages.
Arterial smooth muscle cells (Henriksen et al., 1983; Heinecke et al., 1984) and mouse peritoneal macrophages (Parthasarathy et al., 1986a; Rankin & Leake, 1987 , 1988 Naruszewicz et al., 1989; Jessup et al., 1990) can also modify LDL so that macrophages will take it up faster. The mechanism of LDL modification by cells is not entirely clear but involves lipid peroxidation (Steinbrecher et al., 1984 (Steinbrecher et al., , 1989 Heinecke et al., 1984 Heinecke et al., , 1986 Heinecke et al., , 1987 van Hinsbergh et al., 1986; Steinbrecher, 1987 Steinbrecher, , 1988 Esterbauer et al., 1987; Hiramatsu et al., 1987; Parthasarathy et al., 1989; Cathcart et al., 1989) . LDL has been shown to be oxidized by human monocytes (Cathcart et al., 1985 (Cathcart et al., , 1988 (Cathcart et al., , 1989 , monocyte-derived macrophages , myelomonocytic cell lines U937 and HL60 (Cathcart et al., 1988) and neutrophils (Cathcart et al., 1985) , but its subsequent uptake by macrophages was not reported. Human blood mononuclear cells were shown by Hiramatsu et al. (1987) to oxidize LDL, but the oxidized LDL was apparently not taken up faster than unmodified LDL by J774 macrophages. In one study (Montgomery et al., 1986) , no oxidation of LDL by human mononuclear cells was found. Gorog & Kakkar (1987) have shown that human monocytes can modify LDL so that arterial endothelial cells in vivo will take it up faster.
There is increasing evidence that oxidized LDL is present in atherosclerotic lesions (Shaikh et al., 1988; Haberland et al., 1988; Trakht et al., 1988; Daugherty et al., 1988; Mowri et al., 1988; Palinski et al., 1989; Steinberg et al., 1989 ). It appears, however, that oxidized LDL is not present in the normal arterial wall (Haberland et al., 1988; Trakht et al., 1988; Palinski et al., 1989; Yla-Herttuala et al., 1989) . The normal arterial wall contains endothelial cells and smooth muscle cells, whereas atherosclerotic lesions also contain macrophages and T-lymphocytes (Jonasson et al., 1986 Cohn & Benson (1965) , as described previously . They were plated in 22.6 mm-diam. wells in 12-well cluster plates (Costar; supplied by Northumbria Biologicals Ltd., Cramlington, Northumbria, U.K.), at 2 x 106 peritoneal cells per well for the macrophages that were to modify LDL, and at I x 1 06/well for the macrophages that were to receive the modified LDL.
Isolation and radioiodination of LDL LDL (1.019-1.063 g/ml) was isolated from normal human blood, in the presence of EDTA to slow down auto-oxidation, by sequential density ultracentrifugation, as described previously (Rankin et al., 1989) . It was labelled with Na1251 using ICI (Rankin et al., 1989) . It was found that the labelling efficiency was much higher if 2 mg of LDL (in terms of protein) was labelled (and then diluted with non-labelled LDL) than if 10-20 mg of LDL was labelled at once. Sterile 125I-labelled LDL was stored at 4°C in 154 mM-NaCl, 16.7 mM-NaH2PO4, 21.1 mmNa2HPO4 and 100 ItM-Na2EDTA (pH 7.4). It was discarded after about 1 month from the date on which the blood was drawn. LDL was acetylated as described by Basu et al. (1976) , except that a total of 10 ,ul of acetic anhydride per mg of LDL-protein was used (a 144 molar excess with respect to the total lysyl residues in LDL).
Modification of LDL
To avoid confusion, the macrophages that were used to modify the 1251I-labelled LDL are referred to as 'modifying' macrophages and those that were used to measure the increased rate of uptake of the modified LDL are termed 'target' macrophages. 125I-labelled LDL (100,ug of protein/ml) was incubated with modifying macrophages (macrophage-modified LDL) or cellfree wells (control LDL) in 0.5 ml of Ham's F-10 medium (catalogue no. 12-412; Flow Laboratories Ltd., High Wycombe, Bucks., U.K.) containing 50 ,ug of gentamicin/ml, to which 3 ,uM freshly dissolved FeSO4 had been added. After incubation (usually for 24 h), the medium was centrifuged (1500 g for 10 min at 4°C), to remove any detached cells.
In some experiments, 1251I-labelled LDL was modified by incubating it at 37°C under sterile conditions for up to 24 h at 100,ug of protein/ml in F-10 medium containing gentamicin (50 ,ug/ml) and freshly dissolved CuSO4 (5 or 100 /aM).
Determination of modified LDL degradation by target macrophages
Modified or control '25I-labelled LDL was diluted to 10 ,ug of LDL-protein/ml with Dulbecco's modified Eagle's medium (DMEM) containing foetal calf serum (10 %, v/v) and gentamicin (50 ,ug/ml) (a medium in which macrophages cannot modify LDL, as described in the Results section). It was then incubated for 24 h with target macrophages or cell-free wells (0.5 ml per well) and its rate ofuptake was estimated by measuring the radioactive non-iodide trichloroacetic acid-soluble degradation products released into the medium after the lysosomal degradation of the LDL (Drevon et al., 1981) . At the end of the incubation, 0.4 ml of medium was taken from each well, made up to 1 ml with water and processed as described previously . The degradation products in the cell-free wells were subtracted from those in the medium from the corresponding target macrophages.
After the medium had been removed, the macrophages were washed several times with ice-cold Dulbecco's phosphatebuffered saline containing Ca2l and Mg2+ and solubilized in 600 ,ul of 200 mM-NaOH for 20 min at room temperature. After shaking, 500,1 was taken for the determination of protein by a modified Lowry procedure (Schacterle & Pollak, 1973) .
Re-isolation of modified LDL After incubation with modifying macrophages or cell-free wells, '251I-labelled LDL was re-isolated by adjusting the density of the medium to 1.1 g/ml with solid KBr (Radding & Steinberg, 1960) . It was then centrifuged at 108000 g (ray 64.3 mm) for 18 h at 10°C in an MSE 18 x 6.5 ml titanium rotor (Fisons, Croydon, Surrey, U.K.). The tubes were sliced and the top layer containing the LDL was dialysed against the NaCl/NaH2PO4/ Na2HPO4/Na2EDTA buffer described above. The protein content (Schacterle & Pollak, 1973) , radioactivity and rate of degradation by target macrophages of LDL were then determined.
Materials
Materials not mentioned above were obtained from the following sources: Ham's F-10 medium (powder) deficient in heavy metal ions (FeSO4, CuSO4, ZnSO4) was specially made up by Irvine Scientific, Santa Ana, CA, U.S.A.; vitamin E, acetylsalicylic acid, indomethacin, nordihydroguaiaretic acid and 5'-polyinosinic acid (potassium salt) were from Sigma; and probucol was a gift from Merrel Dow Pharmaceuticals Ltd., Staines, Middlesex, U.K.
RESULTS
Cytotoxicity, lag phase, effect of cell number and re-isolated modified LDL Mouse resident peritoneal macrophages modified 125I-labelled LDL so that target macrophages degraded it much faster than LDL pre-incubated in the absence of cells (Fig. la) . The macrophages that were used to modify the LDL were obviously damaged, in that they became rounded and some detached from the wells. The target macrophages, in which the uptake of the modified LDL was measured, did not appear to be damaged, however, at least as seen under the phase contrast microscope.
The modification of 125I-labelled LDL by macrophages exhibited a lag phase of several hours before a form of LDL was generated that was degraded faster by the target macrophages (Fig. I a) . In this experiment, the modification plateaued at about 12 h but in another time-course experiment (results not shown) it continued to increase between 12 and 24 h. There was a similar lag phase when 125I-labelled LDL was modified by 5 ,tM-CuSO4 in the absence of cells (Fig. lb) . This lag phase was shortened when the CuSO4 concentration was increased . Fig. 2 shows the effect of varying the number of peritoneal cells in each well on the modification of 125I-labelled LDL. It should be noted that only about half of the peritoneal cells are macrophages (Cohn & Benson, 1965) (Table 1 ). The specific activity of the re-isolated 1251_ labelled LDL was not significantly affected by its modification by macrophages.
Dependence of modification on iron
As shown in Fig. 3 , little or no modification of LDL took place when it was incubated with macrophages in Ham's F-10 medium specially formulated to be deficient in heavy metal ions (FeSO4, CuS04, ZnSO4) . Adding 3 or 5 /tM freshly dissolved FeSO4 increased the modification of LDL by macrophages above the control levels. (F-10 is normally formulated to contain 3 /tMFeSO4.) Increasing the concentration further increased the degree of modification, but the control LDL was also modified at 10 ,uMFeSO4 or above so that it was degraded at a similar rate to the macrophage-modified LDL.
Macrophages modified LDL well when incubated in normal Ham's F-10 medium containing heavy metal ions ( The degradation of macrophage-modified LDL by target macrophages showed evidence of saturation as its concentration was increased (Fig. 4) . In this particular experiment, the control LDL (which had been pre-incubated in iron-containing Ham's F-10 medium in cell-free wells) was degraded somewhat faster than native LDL (which had not been pre-incubated). This was sometimes observed in other experiments but often the two types of LDL were degraded at similar rates.
The nature of the binding site for macrophage-modified LDL was determined by competition experiments. The degradation by macrophages of macrophage-modified 125I-labelled LDL (10 ,ug of protein/ml) was inhibited by about 95 % by adding non- labelled acetyl-LDL at a concentration of 50 or 100 ,ug of protein/ml (Fig. 5) . In a similar experiment, about 85-90 % inhibition was observed. 5'-Polyinosinic acid also inhibited the degradation of macrophage-modified l25l-labelled LDL (85°h or more inhibition at 10 pig/ml or above) (Fig. 5) . In contrast, there was much less inhibition (Fig. 5) or no inhibition (results not shown) of macrophage-modified '25I-labelled LDL degradation by non-labelled native LDL. The degradation of copper-oxidized 251-labelled LDL was inhibited strongly by non-labelled acetyl-LDL (about 9500 inhibition at 100 ,ug of acetyl-LDL protein/ml), but not by non-labelled native LDL (Fig. 5) .
Inhibition of LDL modification
Modification of 1251-labelled LDL by macrophages was inhibited by Na2EDTA and by the selective iron chelator desferrioxamine B in a concentration-dependent manner, but relatively high concentrations were required (Fig. 6) . The lipophilic antioxidants butylated hydroxytoluene, vitamin E and nordihydroguaiaretic acid were more effective inhibitors (Table  3 ). The concentrations of Na2EDTA, desferrioxamine and antioxidants that would have been carried over to the target macrophages (one-tenth of the concentration to which the modifying macrophages were exposed) did not affect their degradation of macrophage-modified LDL (results not shown). The cyclo-oxygenase inhibitors acetylsalicylic acid and indomethacin did not inhibit the modification of LDL (Table 3) . As shown in Fig. 7 , the anti-atherosclerotic drug probucol was an effective inhibitor of LDL modification by macrophages, the concentration required to inhibit the modification by 50 % being less than 1 ,UM, with 3 ,tM producing complete inhibition. Probucol, even at a concentration of 10 /tM did not affect the degradation of macrophage-modified LDL by target macrophages. The modification of 125I-labelled LDL by macrophages could be inhibited completely by foetal calf serum (Fig. 8) . A serum concentration of 1 % (v/v) gave about 50 % inhibition.
Lipoprotein-deficient foetal calf serum (which was prepared by adjusting its density to 1.25 g/ml with KBr followed by ultracentrifugation and dialysis) also inhibited LDL modification (results not shown). In contrast to its effects on the modification of LDL by macrophages, whole foetal calf serum (10 %, v/v) had little effect on the modification of LDL by 5 PuM-CuSO4 in Ham's F-10 medium (results not shown).
DISCUSSION
Mouse resident peritoneal macrophages have been shown to modify 125I-labelled LDL so that other macrophages will take it up about 10 times as fast as unmodified LDL (Rankin & Leake, 1987 , 1988 . Similar observations have been made by Parthasarathy et al. (1986a) and Naruszewicz et al. (1989) . This raises the possibility that macrophages may be responsible for modifying much of the oxidized LDL that appears to be formed in atherosclerotic lesions.
Although the 125I-labelled LDL was oxidized by the modifying macrophages, it would have been unlikely to have been further oxidized in these experiments by the target macrophages in which its uptake was measured. This is because the modified LDL was diluted by 1:10 in DMEM containing 100% (v/v) foetal calf serum before it was added to the target macrophages. As shown in this study, macrophages cannot oxidize LDL in DMEM or in the presence of low concentrations of foetal calf serum.
The macrophages that modified the LDL were damaged, probably due to the cytotoxic effects of oxidized LDL (Morel et al., , 1984 Chisolm et al., 1983; Hessler et al., 1983; Cathcart et al., 1985 Cathcart et al., , 1988 Cathcart et al., , 1989 ). The target macrophages to which the oxidized LDL was added, however, did not appear by phase contrast microscopy to be damaged by the LDL. This was probably because serum was present during the incubation of the LDL with the target macrophages (but not during the incubation with the modifying macrophages), and this has been shown to protect cells against the cytotoxic effects of oxidized LDL (Henriksen et al., 1979) . Also, the LDL was added to the target macrophages at only one-tenth of the concentration at which it was added to the modifying macrophages.
The modification of LDL by macrophages or by 5 ,uM-CuSO4 exhibited a time lag of several hours before the uptake of the modified LDL by macrophages was increased. A time lag for the oxidative modification of LDL by endothelial cells (Henriksen et al., 1983) , smooth muscle cells (Heinecke et al., 1984) , monocytes (Cathcart et al., 1989) and auto-oxidation (Esterbauer et al., 1987) has been shown previously. This lag phase is due, at least in part, to the time taken for the endogenous antioxidants, such as vitamin E, to be consumed in LDL, after which there is a rapid rise in the levels of hydroperoxides in LDL (Esterbauer et al., 1987; Jessup et al., 1990) .
When LDL was incubated with macrophages and re-isolated by ultracentrifugation, it was taken up much faster by the target macrophages than was native LDL or re-isolated control LDL. Thus the increased uptake of the macrophage-modified LDL was due to a change in the LDL itself and not to some factor released from the macrophages that increased the uptake of unmodified LDL.
The modification of LDL by the macrophages was dependent on micromolar amounts of iron. Little or no modification was observed in Ham's F-10 medium which had been specially formulated to be deficient in heavy metal ions, but adding FeSO4 to the medium restored the ability of the macrophages to modify LDL. The oxidation of LDL by human mononuclear cells (Hiramatsu et al., 1987) or smooth muscle cells (Heinecke et al., 1984) has also been shown to be increased by iron. If too much FeSO4 was added to our system, however, the LDL was also modified in the cell-free wells. Thus a difference in the modification of LDL by macrophages and cell-free wells was only seen over a rather narrow range of iron concentration (below 10 /uM).
Iron could promote the modification of LDL by initiating lipid peroxidation or by promoting the breakdown of lipid hydroperoxides (Aust et al., 1985; Halliwell & Gutteridge, 1989 (Frankel, 1982) to form a variety of compounds, including aldehydes, which may react with apolipoprotein B-100 (Steinbrecher, 1987; Steinbrecher et al., 1989) . Iron has been shown to bind to phospholipids in liposomes and microsomes (Vile & Winterbourn, 1987) and this raises the interesting possibility that iron-mediated free-radical generation may actually occur on the surfaces of the LDL particles.
Macrophages were able to modify LDL in Ham's F-10 medium containing micromolar amounts of iron, but not in DMEM, even when 3 1uM-FeSO4 was added to it. Endothelial cells (Steinbrecher et al., 1984) , smooth muscle cells (Heinecke et al., 1984) and monocytes (Cathcart et al., 1988 ) also cannot oxidize LDL readily in DMEM. LDL was modified well by 5 prM-CuSO4 when it was added to F-10, but not when it was added to DMEM, and so there is probably an antioxidant factor of some kind present in DMEM.
The macrophage-modified 125I-labelled LDL was taken up by the mouse peritoneal macrophages apparently almost entirely 1990 by the acetyl-LDL receptor, as its degradation was inhibited by about 85-95 % by excess non-labelled acetyl-LDL but much less, or not at all, by non-labelled native LDL. The degradation of copper-oxidized LDL was also inhibited by about 95 % by excess non-labelled acetyl-LDL. In contrast, the degradation of endothelial cell-modified or copper-oxidized 1251I-labelled LDL by mouse peritoneal macrophages was inhibited by only about 50 % by excess non-labelled acetyl-LDL in a study by Sparrow et al. (1989) , who concluded that LDL oxidized by endothelial cells or by copper was taken up by the acetyl-LDL receptor and at least one other receptor. The reason for this difference in our results is unknown.
EDTA partially inhibited the modification of LDL by macrophages, as did the selective Fe3+ chelator desferrioxamine B, but relatively large amounts were required. Desferrioxamine binds Fe3+ (but not Fe2' significantly) so that it is not available for reaction. FeSO4 was added to the Ham's F-10 medium, but autoxidation of Fe2+ may have occurred, especially as this is promoted by desferrioxamine (Klebanoff et al., 1989) , and there may have been redox recycling of Fe2+ and Fe3+ during lipid peroxidation. The iron should therefore in theory have been available for binding to the desferrioxamine. As relatively large amounts of desferrioxamine were required, however, this raises the possibility that it may also have been acting as a scavenger for superoxide anions (Sinaceur et al., 1984) or lipid peroxyl radicals (Darley-Usmar et al., 1989) .
The chain-breaking antioxidants butylated hydroxytoluene and vitamin E totally prevented the modification of LDL, as did the lipid-lowering drug probucol. Similar effects of these compounds have been reported for LDL oxidation by endothelial cells (Steinbrecher et al., 1984; Morel et al., 1984; Parthasarathy et al., 1986b; van Hinsbergh et al., 1986) , smooth muscle cells (Morel et al., 1984; Heinecke et al., 1986) , monocytes (Cathcart et al., 1985 (Cathcart et al., , 1989 Hiramatsu et al., 1987) , macrophages (Parthasarathy et al., 1986a) and neutrophils . A concentration of probucol of 3 /tM completely inhibited LDL modification by the macrophages which agrees with the observation of Parthasarathy et al. (1986b) using endothelial cells. The concentration of probucol in the plasma of hypercholesterolaemic patients treated with this drug is about 100 uM (Parthasarathy et al., 1986b) , and the compound is carried within the plasma lipoproteins, including LDL (Marshall, 1982) . Probucol inhibits spontaneous atherosclerosis in the LDL-receptordeficient WHHL strain of rabbits by an effect that is independent of its plasma-cholesterol-lowering effect, presumably by inhibiting the oxidative modification of LDL within the arterial wall (Carew et al., 1987; Kita et al., 1987) . The structure of probucol is similar to that of butylated hydroxytoluene, and it may be acting as a chain-breaking antioxidant in the LDL particles.
The cyclo-oxygenase inhibitors acetylsalicylic acid and indomethacin, at concentrations that would have completely inhibited the enzyme, did not inhibit the modification of LDL by macrophages. This indicates that free radicals formed as a by-product of this enzymic activity were not essential for the oxidation of LDL. Similar results have been reported by van Hinsbergh et al. (1986) and Parthasarathy et al. (1989) (Gutteridge, 1983) ], extracellular superoxide dismutase (Karlsson & Marklund, 1988) , high-density lipoproteins [which have been reported to inhibit certain aspects of LDL modification (van Hinsbergh et al., 1986; Klimov et al., 1987) ], the serum proteins in general (which may have undergone (sacrificial' oxidation in preference to the LDL) and the antioxidants vitamin E, ascorbic acid, uric acid or bilirubin (Wayner et al., 1987; Frei et al., 1989) . Whatever the nature of the inhibitory factors present in serum, the results suggest that LDL modification may not occur to any significant extent in the circulating blood but may only occur in localized environments, such as in the arterial wall, where the ratio of the oxidant stress to antioxidants may be high. 
